Imaging Immune Activation in COVID-19

This study is looking at how the immune system responds to COVID-19 in people who have recovered. Researchers will use a special imaging technique called PET-CT with a tracer called [18F]F-AraG. This tracer helps them see where activated T cells (a type of immune cell) are located in your body. The main goal is to map out where [18F]F-AraG goes in people who have recovered from COVID-19 for at least four weeks. This information will be compared to people who haven't had COVID-19. You may be able to join if you are over 18, can understand the consent form, and have had a positive COVID-19 test. The study is currently unclear about its recruitment status.

Study design: This is an exploratory imaging study involving up to 80 participants. It is a single-center, single-arm study, meaning all participants receive the same intervention.
What's involved: You will receive up to two intravenous (into the vein) microdoses of [18F]F-AraG, followed by whole-body PET-CT imaging. The second dose and scan are optional and may occur 1 month to one year after the first.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint is measured at 4 weeks after COVID-19 recovery. An optional second imaging visit may occur 1 month to one year after the first.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Imaging Immune Activation in COVID-19

Recruiting

PHASE2Ages 18+InterventionalBasic science

CellSight Technologies, Inc.

~80 participants

Updated 2026-05-08 on ClinicalTrials.gov

What's tested:[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Anatomical distribution of [18F]F-AraG in participant with convalescent COVID-19 greater than 4 weeks (N = 80). Tracer activity will be compared with sex and age-matched uninfected historical control participants enrolled in prior studies.

Measured over 4 weeks

Conditions

Covid19

SARS-CoV Infection

Where it's being run

1 sites across 1 states

California1

Study leadership

Timothy Henrich, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Timothy Henrich, MD

[email protected]

6282065518

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age \>18 years

Ability to read and understand written informed consent document

Have a recent diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples.

\> 14 days since onset of COVID-19 symptoms (or if no symptoms, from time of initial nucleic acid based diagnostic test).

Laboratory evaluations obtained within 60 days prior to entry.

Platelet count ≥75,000/mm3

ANC \>1000/mm3

Aspartate aminotransferase (AST) \<3 x ULN

Alanine aminotransferase (ALT) \<3 x ULN

Calculated creatinine clearance (CrCl) ≥60 mL/min as estimated by the Cockcroft-

Gault equation

Exclusion

Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator

Participants who are pregnant (female participants of childbearing age will be tested prior to injection of imaging agent at entry visit/initial visit - positive test will exclude from further participation in the study)

Participants who are breastfeeding

Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy) must have a negative urine or serum pregnancy test with a sensitivity of at least 25 mIU/mL performed within 24 hours prior to PET imaging. Females of reproductive potential will need to be on 2 forms of birth control (excluding withdrawal or timing methods).

Participants who have had prior allogeneic stem cell or solid organ transplant.

Screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<75,000 cells/mm3, hemoglobin \< 8 mg/dL, estimated creatinine clearance \<60 mL/minute, aspartate aminotransferase \>3 x ULN, alanine aminotransferase \>3 x ULN.

Known SARS-CoV-2 shedding within 5 days of PET imaging.

Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry

Active systemic autoimmune diseases not related to COVID-19.

COVID-19 vaccine prior to the first PET imaging session. Participants may receive COVID-19 vaccination after the first PET imaging session and the optional second PET scan, with the scan being performed at least 2 weeks following the most recent vaccine dose.

Prior PET scan or therapeutic radiation within 1 year of study enrollment.

What this trial measures

Anatomical distribution of [18F]F-AraG in participant with convalescent COVID-19 greater than 4 weeks (N = 80). Tracer activity will be compared with sex and age-matched uninfected historical control participants enrolled in prior studies.4 weeks
To determine regional uptake of \[18F\]F-AraG in participants with convalescent COVID-19.

Trialytics